Indeed, pharmacological inhibition of PLK1 and AURKA demonstrated superior antitumor activity compared with either single drug treatment in nasopharyngeal carcinoma and was minimally harmful to normal epithelial cells. The gene discussed is AURKA; the disease is nasopharyngeal carcinoma.